![Harvey N. Masonson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profile
Harvey N.
Masonson held several positions in the pharmaceutical industry, including Assistant Director-Clinical Safety at Bristol Myers Squibb Co., Director-Clinical Research at Sanofi-Synthelabo, Inc., Vice President-Clinical Development & Drug Safety at (OSI).
Eyetech, and Senior Vice President-Clinical Development at IVERIC bio, Inc. He also served as Vice President-Clinical Development at Gensight Biologics SA from 2018 to 2019.
Masonson earned a doctorate degree from the Icahn School of Medicine at Mount Sinai.
Former positions of Harvey N. Masonson
| Companies | Position | End |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Chief Tech/Sci/R&D Officer | 2018-12-31 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
(OSI) Eyetech
 (OSI) Eyetech Medical SpecialtiesHealth Technology Provides medical services | Corporate Officer/Principal | - |
Sanofi-Synthelabo, Inc. | Chief Tech/Sci/R&D Officer | - |
| IVERIC BIO, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Harvey N. Masonson
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
2
1st degree connections
6
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
(OSI) Eyetech
(OSI) Eyetech Medical SpecialtiesHealth Technology Provides medical services | Health Technology |
Icahn School of Medicine at Mount Sinai
 Icahn School of Medicine at Mount Sinai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IVERIC bio, Inc.
 IVERIC bio, Inc. BiotechnologyHealth Technology Operates as a science-driven biopharmaceutical company that develops novel treatments for retinal diseases | Health Technology |
Sanofi-Synthelabo, Inc. | Health Technology |
Gensight Biologics SA
 Gensight Biologics SA Pharmaceuticals: MajorHealth Technology Manufactures and markets novel therapies for severe retinal neurodegenerative diseases | Health Technology |
- Stock Market
- Insiders
- Harvey N. Masonson
Choose MarketScreener 
